Business
Costas CSSI Appoints new board.
Costas CSSI Appoints new board..
About this update from Standard Dental Labs Inc.
[{"type":"text","content":"COSTAS Inc. (CSSI) Acquires Nanotechnology Company, Appoints New Management and Board Members LAS VEGAS (May 21st 2019) – via NetworkWire - COSTAS,Inc. (OTC: CSSI), announces its acquisition of Atlas Nano Tech (Formerly Know as Nano Creaciones SAPI de CV) in an all-stock transaction that marks the Company’s entrance into the multi-billion-dollar global nanomedicine market. The acquisition coincides with the resignation of COSTA’s current board of directors and the retirement of 12,660,000 shares.The principles of Atlas are receiving 25,000,000 shares subject to a lock-up agreement with staggered release of shares over a 2 year period .Atlas Nano Tech (FKA Nano Creaciones SAPI de CV) is a Guadalajara based high-tech nanotechnology research and development company focused on the field of nanomedicine. The company patents and licenses nanomedicine developments for worldwide distribution. Atlas is focused on bringing to market state-of-the-art products derived from the latest breakthroughs in nanotechnology as it is applied in the medical field. The company has 3 fully developed nanomedical products including a patented nano technology treated gauze used in the treatment of diabetic ulcers and burn patients (nanogasa.com). Nanogasa will reach the worldwide market this year. Atlas is led by a team of highly qualified professionals with outstanding professional backgrounds and reputations. Under this acquisition,COSTA’s new board of directors and controlling parties will comprise Atlas’ executive board, and top operating executives. , as follows:Julio Cesar Riestra Rodriguez MD, has been named chief executive officer. Dr. Julio Riestra is a founder of Atlas Nano Tech and is a practicing surgeon. He will oversee the research and development of the company’s pipeline of medical nanotechnology products. He is committed to the integration of nanotechnology, biosciences and medicine. His primary role as CEO is to coordinate the business development team with the research and development team in order to achieve the highest level of medical nanotechnology, while expeditiously bringing to market unique commercial nanotech products.David Alejandro Lopez de la Mora PhD, will be chairman of the board. Dr. de la Mora has a doctorate in molecular biology, has authored nine books on nano technology and bioscience as well as p...